D. E. Shaw & Co., Inc. Athira Pharma, Inc. Transaction History

D. E. Shaw & Co., Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.9 - $3.16 $39,366 - $65,472	-20,719 Reduced 40.81%	30,049 $60,000
Q2 2023 Aug 14, 2023	SELL	$2.36 - $3.59 $29,986 - $45,614	-12,706 Reduced 20.02%	50,768 $149,000
Q1 2023 May 15, 2023	SELL	$2.26 - $4.22 $200,394 - $374,187	-88,670 Reduced 58.28%	63,474 $158,000
Q4 2022 Feb 14, 2023	BUY	$2.76 - $3.71 $66,300 - $89,121	24,022 Added 18.75%	152,144 $482,000
Q3 2022 Nov 14, 2022	BUY	$2.93 - $3.96 $313,984 - $424,361	107,162 Added 511.27%	128,122 $381,000
Q2 2022 Aug 15, 2022	BUY	$2.74 - $13.43 $12,160 - $59,602	4,438 Added 26.86%	20,960 $64,000
Q1 2022 May 16, 2022	SELL	$8.96 - $13.51 $333,114 - $502,274	-37,178 Reduced 69.23%	16,522 $223,000
Q4 2021 Feb 14, 2022	BUY	$9.17 - $16.39 $492,429 - $880,143	53,700 New	53,700 $700,000

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $24.2M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.